The antidiabetic drug metformin acts on the bone microenvironment to promote myeloma cell adhesion to preosteoblasts and increase myeloma tumour burden in vivo
Open Access
- 8 December 2021
- journal article
- research article
- Published by Elsevier in Translational Oncology
- Vol. 15 (1) , 101301
Abstract
No abstract availableKeywords
Funding Information
- NIHR Oxford Biomedical Research Centre
- International Myeloma Foundation
- Blood Cancer UK (15026)
- National Institute for Health Research
- Versus Arthritis
This publication has 53 references indexed in Scilit:
- The anti-diabetic drug metformin does not affect bone mass in vivo or fracture healingOsteoporosis International, 2013
- Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrowJournal of Clinical Investigation, 2011
- AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone massBone, 2010
- Identification of osteopontin-dependent signaling pathways in a mouse model of human breast cancerBMC Research Notes, 2009
- Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expressionBiochemical and Biophysical Research Communications, 2008
- Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)–dependent migration and homing in multiple myelomaBlood, 2006
- The involvement of osteopontin and its receptors in multiple myeloma cell survival, migration and invasion in the murine 5T33MM modelBritish Journal of Haematology, 2006
- Bone sialoprotein mRNA and protein expression in human multiple myeloma cell lines and patientsBritish Journal of Haematology, 2000
- Bone sialoprotein mRNA and protein expression in human multiple myeloma cell lines and patientsBritish Journal of Haematology, 2000
- Human myeloma cells promote the production of interleukin 6 by primary human osteoblastsBritish Journal of Haematology, 2000